Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of ARQ-151 cream in atopic dermatitis
2021-006885-19Phase 3Completed
- Sponsor
- Arcutis Biotherapeutics
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of roflumilast in atopic dermatitis (AD) (2 arms), sponsored by Arcutis Biotherapeutics. Primary endpoint: Adverse events. Started May 2022; status: completed.
02
Drugs
roflumilast
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2021-006885-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006885-19.